What Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticals

Related Articles

What Just Happened with Day One Biopharmaceuticals and Servier

7 months ago

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

7 months ago

What's Driving Day One's Recent Surge? The Servier Acquisition Explained.

7 months ago

Is Capital One's Bold Acquisition Strategy Paying Off

8 months ago

Category

You may also like

Stock News•10 hours ago

Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network

Cencora agreed to acquire AON for $2.4B to expand its oncology services platform and strengthen community cancer care, supporting long-term growth.

COR

Share

Stock News•2 months ago

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics raised ~$1.55B from selling sevasemten to Servier, extending its cash runway into the early 2030s. The deal self-funds late-stage development of EDG-7500, which showed robust Pha...

EWTX

Share

Stock News•3 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

ABBV

Share